Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JHP who wrote (5986)	3/21/2002 3:19:01 PM
From: LLCF	Read Replies (2) \| Respond to of 52153

<what hype? > Well, I thought anti-angio was widely thought to starve tumors and 'cure' cancer... it turns out that at best it may be used WITH chemo [a very unpleasent and some think barbaric, albeit the best right now] for incremental gains in the fight against cancer. Maybe I'm wrong, that was my impression when Folkmman first presented several years ago and the stock soared. The results certainly look "OK", but there seems to be a lot of exciting stuff around. <or do you just klet other people do your thinking for you? > Oh... I let LOTS of other people do LOTS of my thinking for me, believe me. :) DAK

To: JHP who wrote (5986)	3/24/2002 9:10:37 PM
From: Russ B	Respond to of 52153

ENMD, yeah I've been following it since 1999 when Judah's research was reported here in Chicago Tribune one Sunday.. But with the cancer research, I am following pharmacogenomic co's, and yeah here's my diamond in the rough again, DNAP :) startribune.com 3 years! DNAP says 1 year(AND DNAP'S TEST IS MORE ACCURATE!).....so how come DNAP's part in this article is only a very small paragraph......sheeeeeesh! Mayo identifies genetic markers to help individualize chemo Sharon Schmickle Star Tribune Published Mar 20, 2002 Pushing toward the day when treatments will be tailored to fit a patient's DNA, Mayo Clinic researchers have identified genetic markers to show which women are likely to respond to the chemotherapy most commonly used to fight ovarian cancer. Personalizing chemotherapy could spare thousands of women every year from needless risky treatment and help steer them toward effective alternatives, said Dr. Lynn Hartmann of Mayo who presented the findings Tuesday at a meeting of the Society of Gynecologic Oncologists in Miami. Mayo researchers worked on the study with Millennium Pharmaceuticals Inc. of Cambridge, Mass. Doctors from the University of Miami and DNAPrint genomics Inc. of Sarasota announced similar findings Tuesday from a separate study and said they also are developing a test for screening patients before chemotherapy. The studies are a leading example of applications emerging from the Human Genome Project that promise to transform medicine with treatments that better fit each patient. Currently it is standard practice to treat women who have advanced-stage ovarian cancer with a chemotherapy of paclitaxel and platinum, Hartmann said. While most women derive some benefit, only 15 percent are cured and some don't respond at all. The disease is the fifth-ranking killer among cancers in women. Using computerized genetic analysis, Hartmann's team compared responses and identified 14 genes that could serve as predictive markers. The technique was accurate in 86 percent of the test cases. Further studies are needed, Hartmann said, but screening could be available as early as three years from now.